Medlab Clinical Limited
(ASX:MDC) has been granted ethics approval for Phase 2a of its anti depression study.
The medical research and development company was granted approval to use its patent pending product, NRGBiotic, in a clinical human trial.
The Phase 2a trial follows two successful clinical trials of the product, which saw improved symptoms and quality of life, in patients who suffer from drug resistant depression.
Medlab says its product (NRGBiotic) will not only benefit a significant number of people in Australia and New Zealand, but it will also have a global impact.
Shares in Medlab Clinical Limited
(ASX:MDC) are currently trading 1.15% higher at 88 cents.
